Arsenal Biosciences
Edit info- Founded: 2018
- Location: South SF, CA
- Employee range: 1 - 10
- Clinical stage: Clin0
- Therapy area: Ovarian cancer
- Drug types: ONC
- Lead product: AB-1015
- Funding: $220M B Sep 2022; $85M A Oct 2019
- Investors: Westlake Village BioPartners, the Parker Institute for Cancer Immunotherapy, Kleiner Perkins, UCSF Foundation Investment Company, Euclidean Capital, Osage University Partners, Softbank Vision Fund 2, Bristol-Myers Squibb Company, Byers Capital, Emerson Collective Investments, Green Sands, Hitachi Ventures, Sixth Street
arsenalbio.com linkedin.com job board
Business:
Cancer Treatments
Drug notes:
AB-2100 Clin0 solid tumors
About:
ArsenalBio is developing programmable immune cell therapies to defeat cancer. CAR T-cell therapies are a recent revelation in developing targeted immune therapies for cancer. However, they have high risk and are high cost for development. Using multi-omics, gene editing technology and synthetic biology, ArsenalBio’s cell therapeutics are optimized for expansion, memory and persistence in vivo to reduce the number of cell infusions and minimize off-target effects. ArsenalBio is therefore enhancing the safety, efficacy and availability of these cell therapies for cancer patients. ArsenalBio has a multi program discovery collaboration with Bristol Myers Squibb to advance T cell therapies for solid tumors.
Facilities Coordinator, Contract (26302-T-689-FAC)...Facilities Coordinator, Contra...
Hayward|10 days ago
Senior Research Associate II – Vivarium Operation...Senior Research Associate II –...
South San Francisco|35 days ago
© 2026 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com